Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

You may be eligible if

• Adverse event (AE) report with MedDRA Preferred Term of " John Cunningham virus (JCV) cerebrospinal fluid test positive", " JCV granule cell neuronopathy", or "Progressive multifocal leukoencephalopathy (PML)" reported to the Sponsor between 4-Jun-2026 and 31-Jul-2041.
• AE report(s) originating from spontaneous post-marketing reports, post-marketing observational studies with primary data collection, or patient support programs.
• Diagnosis of multiple sclerosis before the initial AE report.
• Exposure to at least one dose of ozanimod before onset of PML symptoms.
• PML event assessed as "definite" or "probable" by the adjudication committee.
• PML assessed as "related" to ozanimod by the adjudication committee.